advertisement
Goldberg JL 22
Showing records 1 to 22 | Display all abstracts from Goldberg JL124420 Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Chiang B
Drug Delivery 2024; 31: 2379369
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Zhu Y
Experimental Eye Research 2024; 246: 110017
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Huang AS
Clinical Ophthalmology 2024; 18: 3153-3160
124420 Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Heng K
Drug Delivery 2024; 31: 2379369
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Mai AP
Clinical Ophthalmology 2024; 18: 3153-3160
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Nair RV; Xia X
Experimental Eye Research 2024; 246: 110017
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Goldberg JL
Clinical Ophthalmology 2024; 18: 3153-3160
124420 Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Jang K; Dalal R
Drug Delivery 2024; 31: 2379369
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Samuelson TW
Clinical Ophthalmology 2024; 18: 3153-3160
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Nahmou M
Experimental Eye Research 2024; 246: 110017
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Morgan WH
Clinical Ophthalmology 2024; 18: 3153-3160
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Li X
Experimental Eye Research 2024; 246: 110017
124420 Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Liao YJ
Drug Delivery 2024; 31: 2379369
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Herndon L
Clinical Ophthalmology 2024; 18: 3153-3160
124420 Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Myung D
Drug Delivery 2024; 31: 2379369
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Yan W
Experimental Eye Research 2024; 246: 110017
124420 Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Goldberg JL
Drug Delivery 2024; 31: 2379369
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Li J
Experimental Eye Research 2024; 246: 110017
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Ferguson TJ
Clinical Ophthalmology 2024; 18: 3153-3160
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Tanasa B
Experimental Eye Research 2024; 246: 110017
119325 The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma
Weinreb RN
Clinical Ophthalmology 2024; 18: 3153-3160
123554 Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide
Goldberg JL; Kapiloff MS
Experimental Eye Research 2024; 246: 110017
